In-Space Manufacturing’s Billion-Dollar Problem: Great Science, No Business Model

Key Takeaways

• Decades of ISS research have yet to produce a single commercially viable manufactured product from orbit
• Launch costs remain the central economic barrier, even after significant reductions from reusable vehicles
• Varda Space Industries represents the most credible near-term test case, but its path to profitability remains unproven

A Promise With a Very Long Track Record of Not Delivering

The idea of manufacturing products in the microgravity environment of space has been circulating in aerospace research circles since the earliest days of the International Space Station. The logic is straightforward: certain materials, biological structures, and optical components behave differently when freed from the constraints of gravity. Protein crystals grow larger and more uniformly. Fiber optic cables can theoretically be drawn without the defects that terrestrial manufacturing inevitably introduces. Metal alloys mix without the density-driven separation that occurs in Earth-bound foundries. The science is real. The commercial application has remained, for decades, elusive.

The gap between fascinating microgravity physics and a manufacturable, sellable product shipped back through reentry at a cost that makes economic sense has swallowed enormous quantities of research funding, investor capital, and optimism. The question isn’t whether interesting things can be made in space. They can. The question is whether they can be made at a price that any customer would actually pay, and that question has never received a satisfying answer.

The ZBLAN Story

No product better illustrates the gap between microgravity promise and commercial reality than ZBLAN fiber optic cable. ZBLAN is a heavy-metal fluoride glass capable of transmitting infrared wavelengths with theoretical attenuation far lower than conventional silica fiber. Made on Earth, ZBLAN fiber suffers from crystallization defects that degrade its performance and prevent it from achieving anything close to its theoretical limits. In microgravity, the suppression of convection and the absence of gravitational settling allow ZBLAN to solidify with dramatically fewer crystalline inclusions, producing a fiber that comes much closer to its theoretical transmission characteristics.

Researchers and entrepreneurs have been aware of this for more than two decades. Made In Space, now operating as part of Redwire Corporation after a 2020 acquisition, ran experiments aboard the ISS as part of its commercial manufacturing research. The company’s ZBLAN work demonstrated that higher-quality fiber could indeed be produced in orbit. The problem that was never solved was the economics.

ZBLAN fiber competes in a niche market for specialty infrared transmission applications in medical, sensing, and defense systems. The total addressable market for this fiber is measured in the tens of millions of dollars annually, not billions. To manufacture ZBLAN in orbit commercially, a company would need to launch manufacturing equipment to the ISS or a successor platform, pay for crew time or an automated facility, and then return the finished product to Earth through a reentry capsule. At current launch and ISS access costs, the per-kilogram cost of returning material from orbit runs into the tens of thousands of dollars. ZBLAN fiber, however pure, cannot support that cost structure.

The terrestrial ZBLAN fiber manufacturing industry, meanwhile, has not stood still. Ground-based manufacturers have improved their crystallization control through process refinements and specialized cooling techniques. The performance gap that made orbital production theoretically attractive has been narrowing, even if it hasn’t closed entirely.

The Crystal Medicine Argument

A second major category of proposed in-space manufacturing involves pharmaceutical protein crystal growth. Proteins are among the most difficult structures to crystallize on Earth because their large, complex molecular architectures are easily disrupted by gravity-driven convection currents during the crystallization process. Better crystals enable better X-ray crystallography, which in turn yields more detailed structural information about drug targets, potentially accelerating the development of new therapeutics.

This argument was compelling enough that Merck partnered with NASA in the early 2010s to crystallize the monoclonal antibody pembrolizumab aboard the ISS, seeking a formulation that could be delivered by subcutaneous injection rather than intravenous infusion. The results were scientifically interesting and received significant media attention. What they did not produce was a commercially deployed space-manufactured drug product.

The challenge is that pharmaceutical manufacturing requires not just crystal growth but an entire supply chain: formulation, sterility assurance, stability testing, packaging, and regulatory approval from agencies like the FDA. None of these downstream requirements are easier to meet for a product made in orbit. The regulatory pathway for a drug manufactured in a location subject to microgravity, cosmic radiation, and limited quality control oversight has never been clearly defined, let alone successfully navigated.

Eli Lilly and Bristol Myers Squibb have both participated in ISS crystallography research. The publications resulting from that work have advanced basic science. A commercially manufactured space-produced pharmaceutical remains hypothetical.

Varda Space Industries: The Current Best Test Case

The most credible near-term attempt to actually produce and return a commercially relevant product from orbit belongs to Varda Space Industries, a Los Angeles-based startup founded in 2020 that has raised more than $50 million in venture funding. Varda’s approach is to use a small satellite equipped with a pharmaceutical manufacturing module, produce crystalline drug compounds in orbit using the microgravity environment, and return the results in a reentry capsule.

Varda’s first mission, W-Series 1, launched in June 2023 aboard a SpaceX Falcon 9 rideshare. The spacecraft was built around a Rocket Lab photon bus and carried a small pharmaceutical manufacturing payload working with the antiviral drug ritonavir. The mission experienced a significant complication when the FAA declined to approve reentry over U.S. territory, citing unresolved regulatory issues with commercial reentry licensing. The spacecraft spent months in orbit waiting for approval before eventually reentering and landing at a Utah Test and Training Range facility in February 2024.

The ritonavir crystals produced during the mission were subsequently analyzed and the company reported that the experiment functioned as intended. Whether the resulting crystals represent a commercially viable manufacturing output, one that could be sold at a price justifying the cost of the entire mission, has not been publicly demonstrated. Varda is progressing toward additional missions and has signed agreements with pharmaceutical partners whose names have not been fully disclosed. The company is ly pushing the frontier of commercial in-space manufacturing, but it is doing so at a stage where the fundamental economic equation remains unresolved.

The Launch Cost Floor

Advocates of in-space manufacturing frequently argue that falling launch costs will eventually make the economics work. SpaceX’s Falcon 9 has reduced the cost of sending a kilogram to low Earth orbit from approximately $50,000 in the Space Shuttle era to roughly $3,000. Starship, if it achieves its design goals and rapid reusability, could theoretically bring that cost down to a few hundred dollars per kilogram within the next decade.

That trajectory is real and it matters. But it doesn’t dissolve the business model problem, it just resets the cost floor at a lower number. The manufactured products still need to be valuable enough to justify not only the launch cost but also the cost of the orbital manufacturing facility, the reentry capsule, range fees, regulatory compliance, and the labor intensive process of actually operating a manufacturing process in space.

For products worth a few thousand dollars per kilogram, even a greatly reduced launch cost leaves manufacturing in orbit economically inviable compared to manufacturing on Earth. For products worth tens or hundreds of thousands of dollars per kilogram, the economics can work in principle. The universe of products meeting that criterion while also depending specifically on the microgravity environment for their quality is smaller than the in-space manufacturing industry’s promotional materials suggest.

Redwire’s Pivot and What It Reveals

Redwire Corporation, which went public through a SPAC merger in 2021 at a valuation implying significant confidence in space manufacturing revenue, has undergone a notable evolution in its stated business focus since then. While it continues to describe in-space manufacturing as part of its portfolio, the company’s revenue base has been dominated by spacecraft components, solar arrays, antennas, and electronics rather than by manufactured products sold to end-use commercial customers. The ZBLAN fiber commercialization program that had been a flagship initiative of Made In Space effectively stalled after the acquisition.

Redwire’s stock performance following its SPAC debut tracked poorly through 2022 and 2023, reflecting broader skepticism about space economy SPACs as well as company-specific concerns about revenue growth and the distance between the manufacturing vision and actual financial results. The company has remained a functioning enterprise with engineering capabilities, but its trajectory illustrates how difficult it is to build a profitable business on the promise of orbital manufacturing at the current stage of technological and economic development.

In-Space Assembly: A Different Framing

Some proponents have shifted from the language of manufacturing to the language of in-space assembly, arguing that orbital construction of large structures, specifically solar power satellites, large telescopes, and deep space vehicles, represents the more compelling near-term opportunity. This framing has some merit. Assembling a large structure in orbit from components launched separately is technically more tractable than manufacturing a novel product from raw materials in a microgravity facility.

But the business model challenges are similar. NASA’s OSAM-1 mission, designed to demonstrate satellite refueling and assembly technologies, was cancelled in 2024 after its cost ballooned from an initial estimate of $154 million to more than $2 billion without completing its intended scope. The Archinaut technology demonstration by Made In Space, which was intended to show robotic in-space manufacturing of structural elements, was also cancelled before reaching flight. These programs had technical merit, but they consistently encountered the combination of cost escalation, schedule delay, and unclear commercial demand that characterizes the broader sector.

What the ISS Research Record Actually Shows

The International Space Station has hosted in-space manufacturing experiments for more than two decades. The honest summary of that research record is that it has been extraordinarily valuable for scientific understanding of microgravity effects on materials and biology, and commercially negligible in terms of products that have reached the market.

That isn’t a criticism of the science. The ISS was designed as a research platform, not a production facility, and it functions as one admirably. But the translation from research demonstration to commercial production has failed to materialize at the pace and scale that the industry’s promotional narrative implied. NASA’s Center for the Utilization of Research in Space has published thousands of research results from ISS experiments. The number of those results that have produced a commercially manufactured product available for purchase from any catalog is, by every available count, zero.

The Terrestrial Competition Problem

In-space manufacturing faces a competitor that never sleeps and has been continuously improving for decades: advanced materials manufacturing on Earth. The crystallization defects that make ZBLAN fiber impure on the ground have been targeted by researchers who see a large potential market and don’t need to launch anything to solve the problem. Pharmaceutical crystal growth has been addressed through microfluidics, controlled atmosphere processing, and additive manufacturing techniques that continue to improve year over year.

The assumption embedded in the in-space manufacturing thesis is that the gap between what can be made in microgravity and what can be made on Earth is large and stable enough to support a durable business. In practice, that gap has proven to be a moving target. Every year that in-space manufacturing fails to achieve commercial scale is a year in which terrestrial manufacturing technology closes the performance gap further.

Commercial Space Stations and the Next Chapter

The post-ISS era is expected to include commercially operated low Earth orbit space stations, with Axiom Space building modules on the ISS before operating independently, and companies like Nanoracks through its Starlab partnership and Sierra Space developing their own platforms. These facilities, if they launch on schedule and operate as planned, will offer in-space manufacturing capacity with a different cost structure than the ISS.

Whether that different cost structure will be lower enough to unlock the business models that have eluded the industry so far depends on assumptions about station operating costs, launch prices, and the regulatory frameworks governing commercial station operations, none of which have yet been validated in practice. It’s possible that the next generation of facilities will finally produce the commercial breakthrough that has been anticipated since the 1990s. It’s equally possible that they will host the same research demonstrations and the same commercially inconclusive results that have characterized the ISS era, only with a different set of private investors absorbing the losses.

Summary

In-space manufacturing occupies an unusual position in the space economy: it is one of the most scientifically credible and commercially unproven segments simultaneously. The physics that make it interesting are real. The gap between interesting physics and a product that someone will pay more for than it costs to make and return from orbit has never been bridged at commercial scale. Falling launch costs help, but they don’t resolve the fundamental economics when the products being manufactured compete with terrestrial alternatives that are getting better every year.

The industry’s advocates have been saying “just wait until launch costs come down” for two decades. Launch costs have come down. The commercial breakthrough has not arrived on schedule. That pattern deserves more weight in any honest assessment of where in-space manufacturing stands and where it’s headed.

Appendix: Top 10 Questions Answered in This Article

What is in-space manufacturing and why is it considered commercially promising?
In-space manufacturing refers to producing materials or products in the microgravity environment of orbit, where the absence of gravity-driven convection, sedimentation, and buoyancy allows certain materials to form with fewer defects than is possible on Earth. Proponents have argued this advantage justifies the cost of orbital production for high-value products like specialty fiber optics and pharmaceutical compounds.

Why has ZBLAN fiber optic cable not been commercially manufactured in space despite decades of research?
ZBLAN fiber produced in microgravity has demonstrably fewer crystalline defects than ground-produced fiber, but the total addressable market for ZBLAN is small and the cost of orbital production, including launch, ISS access, and return via reentry capsule, far exceeds what the market will bear. Terrestrial manufacturing techniques have also continued to improve, narrowing the performance gap.

What is Varda Space Industries and what has it accomplished?
Varda Space Industries is a Los Angeles-based startup founded in 2020 that is attempting to commercially manufacture pharmaceutical compounds in orbit and return them in small reentry capsules. Its first mission in 2023 produced ritonavir crystals in orbit and returned them in early 2024, but the commercial viability of the resulting product has not yet been publicly demonstrated.

Why haven’t pharmaceutical companies commercially deployed drugs manufactured in space?
Orbital pharmaceutical manufacturing faces not only the cost challenge of launch and return logistics but also the unresolved regulatory pathway for approving drugs produced in a microgravity environment with limited quality control infrastructure. Agencies like the FDA have not established clear frameworks for certifying space-manufactured pharmaceutical products.

How much has SpaceX reduced launch costs and does it solve the in-space manufacturing problem?
SpaceX’s Falcon 9 reduced the cost of sending a kilogram to low Earth orbit from roughly $50,000 in the Space Shuttle era to approximately $2,700 to $3,000 in rideshare configurations. While this reduction is significant, it doesn’t resolve the manufacturing economics for products that don’t command prices of tens of thousands of dollars per kilogram, since facility costs, regulatory compliance, and return logistics must also be covered.

What happened to Made In Space’s in-space manufacturing programs after Redwire acquired it?
Made In Space was acquired by Redwire Corporation in 2020. The ZBLAN fiber commercialization program that had been a flagship Made In Space initiative effectively stalled after the acquisition. Redwire’s subsequent revenue base has been dominated by spacecraft components and structural hardware rather than commercially manufactured orbital products.

What does the ISS’s 20-plus-year research record show about in-space manufacturing?
The ISS has hosted in-space manufacturing experiments since the early 2000s and produced thousands of scientific publications. However, none of those experiments has resulted in a commercially manufactured product available for purchase at any scale, demonstrating the persistent gap between microgravity research demonstration and viable commercial production.

What is in-space assembly and how does it differ from manufacturing?
In-space assembly refers to constructing large structures in orbit from components launched separately, rather than manufacturing novel materials from raw inputs. It has been proposed as a more near-term path to orbital value creation than manufacturing, with applications including large solar power satellites and modular space telescopes. NASA’s OSAM-1 program, intended to demonstrate related technologies, was cancelled in 2024 after its costs exceeded $2 billion.

Are commercial space stations expected to change the economics of in-space manufacturing?
Axiom Space, Starlab, and Sierra Space are developing commercial low Earth orbit platforms intended to succeed the ISS. Lower operating costs on private stations could reduce access fees for manufacturing experiments, potentially improving the economics for certain products. Whether those cost reductions will be sufficient to enable profitable manufacturing operations has not been validated.

Why do terrestrial manufacturing advances undermine the in-space manufacturing thesis?
The in-space manufacturing argument relies on a persistent performance gap between what can be made in microgravity and what can be made on Earth. Advanced terrestrial manufacturing techniques, including microfluidics, precision environmental control, and additive manufacturing, have been steadily closing that gap. Every year of delay in achieving commercial orbital production is a year in which ground-based alternatives improve.